摘要
目的：探讨利妥昔单抗联合CHOP方案治疗非霍奇金淋巴瘤的临床效果。方法选择本院2012年5月~2014年5月收治的非霍奇金淋巴瘤患者30例，将其随机分为观察组和对照组各15例。对照组患者采用CHOP方案进行治疗，观察组患者在对照组治疗的基础加用利妥昔单抗联合治疗，比较两组的临床疗效。结果观察组治疗有效率为80.0%，高于对照组的60.0%，差异有统计学意义（P〈0.05）；观察组不良反应发生率为53.3%，对照组不良反应发生率为60.0%，差异无统计学意义（P〉0.05）。结论利妥昔单抗联合CHOP方案治疗非霍奇金淋巴瘤效果显著，值得临床推广。
Objective To analyze the clinical effect of rituximab combined with CHOP in the treatment of non-Hodgkin lymphoma. Methods 30 patients with non-Hodgkin lymphoma in our hospital from May 2012 to May 2014 were select-ed,and were randomly divided into observation group （n=15） and control group （n=15）.The control group were given with CHOP treatment,while the rituximab was added to the observation group on the basis of control group.The clinical efficacy was compared between the two groups. Results The effective rate of the observation group was 80.0%,higher than 60.0% of the control group,the difference was significant （P〈0.05）;the incidence of adverse reactions in the obser-vation group was 53.3%,which of the control group was 60.0%,there was no significant difference （P〉0.05）. Conclusion The clinical effect of rituximab combined with CHOP for non-Hodgkin lymphoma is significant,is worthy of clinical promotion.
出处
《中国当代医药》
2014年第26期101-102,105,共3页
China Modern Medicine
